Trial Profile
Randomized ph. II Study to Explore Efficacy and Feasibility of Upfront Rotations Between SUNitinib and Everolimus vs Sequential Treatment of 1st lIne Sunitinib & 2nd Line EverolimuS Until Progression in Pats Met. Clear Cell Renal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sunitinib (Primary)
- Indications Adenocarcinoma; Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SUNRISES
- 12 Jul 2020 Primary endpoint (Progression-free survival (PFS) rate) has not been met.
- 12 Jul 2020 Results published in the BJU International.
- 29 Sep 2017 Status changed from recruiting to discontinued.